Eledon Pharmaceuticals (ELDN) 10-Q 10 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 08, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Trading Symbol	ELDN
Entity Registrant Name	ELEDON PHARMACEUTICALS, INC.
Entity Central Index Key	0001404281
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		23,545,130
Entity File Number	001-36620
Entity Tax Identification Number	20-1000967
Entity Address, Address Line One	19900 MacArthur Blvd
Entity Address, Address Line Two	Suite 550
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92612
City Area Code	(949)
Local Phone Number	238-8090
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 40,947,000		$ 56,409,000
Short-term investments	30,431,000		0
Prepaid expenses and other current assets	2,244,000		3,109,000
Total current assets	73,622,000		59,518,000
Operating lease asset, net	553,000		739,000
In-process research and development	32,386,000		32,386,000
Other assets	224,000		150,000
Total assets	106,785,000		92,793,000
Current liabilities:
Accounts payable	2,197,000		2,200,000
Current operating lease liabilities	390,000		363,000
Accrued expenses and other liabilities	2,313,000		3,912,000
Total current liabilities	4,900,000		6,475,000
Deferred tax liabilities	1,752,000		1,752,000
Non-current operating lease liabilities	184,000		383,000
Total liabilities	6,836,000		8,610,000
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, $0.001 par value, 200,000,000 shares authorized at June 30, 2023 and December, 31, 2022; 23,043,933 and 13,776,788 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	23,000		14,000
Additional paid-in capital	323,142,000		287,034,000
Accumulated deficit	(223,216,000)		(202,865,000)
Total stockholders’ equity	99,949,000	$ 74,792,000	84,183,000
Total liabilities and stockholders’ equity	106,785,000		92,793,000
Series X1 Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Series X Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	23,043,933	13,776,788
Common stock, shares outstanding	23,043,933	13,776,788
Series X1 Non-voting Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	515,000	515,000
Preferred stock, shares issued	110,086	117,970
Preferred stock, shares outstanding	110,086	117,970
Series X Non-voting Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	4,422	6,204
Preferred stock, shares outstanding	4,422	6,204

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses
Research and development	$ 7,201	$ 5,743	$ 15,314	$ 12,378
General and administrative	3,153	3,540	6,150	6,764
Total operating expenses	10,354	9,283	21,464	19,142
Loss from operations	(10,354)	(9,283)	(21,464)	(19,142)
Other income, net	775	36	1,113	31
Net loss and comprehensive loss	$ (9,579)	$ (9,247)	$ (20,351)	$ (19,111)
Net loss per share, Basic	$ (0.4)	$ (0.65)	$ (1.06)	$ (1.34)
Net loss per share, Diluted	$ (0.4)	$ (0.65)	$ (1.06)	$ (1.34)
Weighted-average common shares outstanding, Basic	24,006,549	14,265,905	19,173,080	14,299,969
Weighted Average Number of Shares Outstanding, Diluted	24,006,549	14,265,905	19,173,080	14,299,969

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Series X1 Non-voting Convertible Preferred Stock [Member]	Series X Non-Voting Convertible Preferred Stock [Member]
Beginning Balance at Dec. 31, 2021	$ 163,995	$ 14	$ 278,880	$ (114,899)
Beginning Balance, Shares at Dec. 31, 2021		14,306,788			108,070	6,204
Cancellation of common stock in connection with exchange for preferred stock	1		1
Cancellation of common stock in connection with exchange for preferred stock, Shares		(550,000)			9,900
Stock-based compensation	2,186		2,186
Net loss and comprehensive loss	(9,864)			(9,864)
Ending Balance at Mar. 31, 2022	156,318	$ 14	281,067	(124,763)
Ending Balance, Shares at Mar. 31, 2022		13,756,788			117,970	6,204
Beginning Balance at Dec. 31, 2021	163,995	$ 14	278,880	(114,899)
Beginning Balance, Shares at Dec. 31, 2021		14,306,788			108,070	6,204
Net loss and comprehensive loss	(19,111)
Ending Balance at Jun. 30, 2022	149,379	$ 14	283,375	(134,010)
Ending Balance, Shares at Jun. 30, 2022		13,756,788			117,970	6,204
Beginning Balance at Mar. 31, 2022	156,318	$ 14	281,067	(124,763)
Beginning Balance, Shares at Mar. 31, 2022		13,756,788			117,970	6,204
Stock-based compensation	2,308		2,308
Net loss and comprehensive loss	(9,247)			(9,247)
Ending Balance at Jun. 30, 2022	149,379	$ 14	283,375	(134,010)
Ending Balance, Shares at Jun. 30, 2022		13,756,788			117,970	6,204
Beginning Balance at Dec. 31, 2022	84,183	$ 14	287,034	(202,865)
Beginning Balance, Shares at Dec. 31, 2022		13,776,788			117,970	6,204
Stock-based compensation	1,381		1,381
Net loss and comprehensive loss	(10,772)			(10,772)
Ending Balance at Mar. 31, 2023	74,792	$ 14	288,415	(213,637)
Ending Balance, Shares at Mar. 31, 2023		13,776,788			117,970	6,204
Beginning Balance at Dec. 31, 2022	84,183	$ 14	287,034	(202,865)
Beginning Balance, Shares at Dec. 31, 2022		13,776,788			117,970	6,204
Net loss and comprehensive loss	(20,351)
Ending Balance at Jun. 30, 2023	99,949	$ 23	323,142	(223,216)
Ending Balance, Shares at Jun. 30, 2023		23,043,933			110,086	4,422
Beginning Balance at Mar. 31, 2023	74,792	$ 14	288,415	(213,637)
Beginning Balance, Shares at Mar. 31, 2023		13,776,788			117,970	6,204
Issuance of common stock in connection with PIPE transaction, net of issuance costs, Shares		8,730,168
Issuance of common stock in connection with PIPE transaction, net of issuance costs, Value	33,017	$ 9	33,008
Issuance of common stock in connection with conversion of X non-voting convertible preferred stock, Shares		99,000				(1,782)
Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Shares		437,977			(7,884)
Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Value	(1)		(1)
Stock-based compensation	1,720		1,720
Net loss and comprehensive loss	(9,579)			(9,579)
Ending Balance at Jun. 30, 2023	$ 99,949	$ 23	$ 323,142	$ (223,216)
Ending Balance, Shares at Jun. 30, 2023		23,043,933			110,086	4,422

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash flows used in operating activities:
Net loss used in the calculation of basic and diluted loss per share	$ (9,579)	$ (10,772)	$ (9,247)	$ (9,864)	$ (20,351)	$ (19,111)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of operating lease asset					186	187
Accretion on Investment Discounts					(97)
Stock-based compensation	1,720		2,308		3,101	4,494
Changes in operating assets and liabilities:
Prepaid expenses and other assets					791	1,282
Accounts payable, accrued expenses and other liabilities					(1,603)	(1,042)
Operating lease liabilities					(172)	(183)
Net cash used in operating activities					(18,145)	(14,373)
Cash flows from investing activities:
Purchase of available-for-sale short-term investments					(30,334)
Net cash used in investing activities					(30,334)
Cash flows from financing activities:
Proceeds from issuances of common stock and pre-funded warrants, net					33,017
Net cash used in financing activities					33,017
Net change in cash and cash equivalents					(15,462)	(14,373)
Cash and cash equivalents at beginning of period		$ 56,409		$ 84,833	56,409	84,833
Cash and cash equivalents at end of period	$ 40,947		$ 70,460		40,947	70,460
Noncash activities:
Common stock exchanged for X and X1 non-voting convertible preferred stock					$ 1	$ 1

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its immunology expertise in targeting the CD40 Ligand (“CD40L”, also called “CD154”) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (“ALS”). The Company’s lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that we believe has broad therapeutic potential. Unless otherwise indicated, references to the terms “Eledon,” “our,” “us,” “we,” or the “Company” refer to Eledon Pharmaceuticals, Inc. and its wholly owned subsidiaries, on a consolidated basis. On September 14, 2020 , Eledon acquired Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company developing a next generation anti-CD40L antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. The Company maintains its corporate headquarters in Irvine, California and has research and development facilities in Burlington, Massachusetts.

Going Concern and Management's

Going Concern and Management's Plans	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Plans	Note 2. Going Concern and Management’s Plans The accompanying condensed consolidated financial statements have been prepared under the assumption the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. The Company had a net loss of $ 20.4 million for the six months ended June 30, 2023 and an accumulated deficit of $ 223.2 million as of June 30, 2023, as a result of incurring losses since its inception. The Company expects to continue to incur net losses into the foreseeable future in connection with its ongoing activities, particularly as the Company expands its clinical program with tegoprubart, continues the research and development of, and seeks marketing approval for, its product candidates. In addition, if the Company obtains marketing approval for any of its product candidates, the Company expects to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. The Company has financed operations primarily by net proceeds from the sale of preferred and common stock and warrants. On April 28, 2023, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) shares of common stock and warrants in a series of three potential closings. On May 5, 2023, the initial closing occurred and the Company received $ 35.0 million, in exchange for 8,730,168 shares of common stock, pre-funded warrants to purchase 6,421,350 shares of common stock and additional common stock warrants to purchase 15,151,518 shares of common stock (or pre-funded warrants in lieu thereof). The Company may receive up to an additional $ 105.0 million in tranche financing in a second and a third closing, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional $ 45.5 million assuming the exercise of all common stock warrants issued in the initial closing of the Private Placement. See Note 9. “Stockholders’ Equity” for further information regarding the Private Placement. Due to the contingent nature of the exercise of the common stock warrants and the second and third closings of the Private Placement, accounting principles generally accepted in the United States of America (“GAAP”) requires the Company to exclude them from its going concern analysis. If these events do not occur or the Company is unable to secure additional capital or is unable to do so on acceptable terms, it will be forced to significantly alter its business strategy, substantially curtail its current operations, or liquidate and cease operations altogether. As of June 30, 2023, the Company had cash and cash equivalents and short-term investments of approximately $ 71.4 million. Additionally, in view of the Company’s expectation to incur significant losses for the foreseeable future, the Company will be required to raise additional capital resources in order to fund its operations, although the availability of, and the Company’s access to, such resources is not assured. Accordingly, management believes that there is substantial doubt regarding the Company’s ability to continue operating as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and Article 8 of Regulation S-X requirements as set forth by the Securities and Exchange Commission (“SEC”) for interim financial information and reflect all adjustments and disclosures, which are, in the opinion of management, of a normal and recurring nature, and considered necessary for a fair presentation of the financial information contained herein. Pursuant to these rules and regulations, the unaudited condensed consolidated financial statements do not include all information and notes necessary for a complete presentation of results of operations and comprehensive loss, financial position, and cash flows in conformity with GAAP. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and accompanying notes of Eledon for the year ended December 31, 2022 included in the Annual Report on Form 10-K filed by the Company with the SEC on March 30, 2023. The results of operations and comprehensive loss for the three and six months ended June 30, 2023 are not necessarily indicative of results expected for the full fiscal year or any other future period. Principles of Consolidation Eledon, a Delaware corporation, owns 100 % of the issued and outstanding common stock or other ownership interest in Anelixis Therapeutics, LLC, a Delaware limited liability company, and Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel (“Otic”). Otic owns 100 % of the issued and outstanding common stock or other ownership interest in its U.S. subsidiary, Otic Pharma, Inc. The functional currency of the Company’s foreign subsidiary is the U.S. Dollar; however, certain expenses, assets and liabilities are transacted at the local currency. These transactions are translated from the local currency into U.S. Dollars at exchange rates during or at the end of the reporting period. The activities of the Company’s foreign subsidiary are not significant to the condensed consolidated financial statements. All significant intercompany accounts and transactions among the entities have been eliminated from the condensed consolidated financial statements. Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements. Concentration of Credit Risk Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, U.S. government securities and U.S. government agency securities. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments. Risks and Uncertainties As of June 30, 2023 and December 31, 2022, all of the Company’s long-lived assets were located in the United States. The Company’s products will require approval from the U.S. Food and Drug Administration (“FDA”) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company’s business in the future. In addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process. The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional financing. Our facilities and equipment, including those of our suppliers and vendors, may be affected by natural or man-made disasters. Our administrative office is based in Irvine, California and we manage all our research and development activities through third parties that are located throughout the world. We have taken precautions to safeguard our facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, our facilities and systems, as well as those of our third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in our operations, damage or destroy our equipment or inventory, and cause us to incur additional expenses and delay research and development activities. In addition, the insurance coverage we maintain may not be adequate to cover our losses in any circumstance and may not continue to be available to use on acceptable terms, or at all. Research and Development Expenses Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed. The Company contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company’s accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company’s prior‑period accrued estimates for clinical trial activities during the three and six months ended June 30, 2023 . Recently Adopted Accounting Pronouncements No new accounting pronouncement issued or effective during the fiscal period had or is expected to have a material impact on the Company’s condensed consolidated financial statements or disclosures.

Short-Term Investments

Short-Term Investments	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Short-Term Investments	Note 4. Short-Term Investments The objectives of the Company’s investment policy are to preserve principal, achieve liquidity requirements and safeguard invested funds. Short-term investments consist of U.S. government securities and U.S. government agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized. The following is a summary of short-term investments, which were classified as available-for-sale securities as of June 30, 2023: June 30, 2023 Amortized Cost Fair Value U.S. government securities $ 17,642 $ 17,642 U.S. government agency securities 12,789 $ 12,789 Total short-term investments $ 30,431 $ 30,431 There were no short-term investments as of December 31, 2022 . All of the Company's available-for-sale securities have a stated maturity of less than one year.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Text Block [Abstract]
Fair Value Measurements	Note 5. Fair Value Measurements Financial assets and liabilities are recorded at fair value. The Company classifies fair value measurements using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: • Level 1—Quoted market prices (unadjusted) in active markets for identical assets and liabilities. • Level 2—Observable inputs other than quoted market prices included in Level 1, such as quoted market prices for markets that are not active or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. These fair values are obtained from independent pricing services which utilize Level 1 and Level 2 inputs. The following summarizes the Company's financial instruments measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions. June 30, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 5,143 $ — $ — $ 5,143 U.S. government securities — 32,843 — 32,843 U.S. government agency securities — 993 — 993 Total cash equivalents $ 5,143 $ 33,836 $ — $ 38,979 Short-term investments: U.S. government securities $ — $ 17,642 $ — $ 17,642 U.S. government agency securities — 12,789 — 12,789 Total short-term investments $ — $ 30,431 $ — $ 30,431 Total financial assets $ 5,143 $ 64,267 $ — $ 69,410 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 9,296 $ — $ — $ 9,296 U.S. government securities — — — — U.S. government agency securities — — — — Total cash equivalents $ 9,296 $ — $ — $ 9,296 Short-term investments: U.S. government securities $ — $ — $ — $ — U.S. government agency securities — — — — Total short-term investments $ — $ — $ — $ — Total financial assets $ 9,296 $ — $ — $ 9,296

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	Note 6. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): June 30, December 31, 2023 2022 Prepaid insurance $ 315 $ 823 Prepaid clinical 1,445 2,115 Prepaid other 246 143 Other current assets 238 28 Total prepaid expenses and other current assets $ 2,244 $ 3,109

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Liabilities	Note 7. Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following (in thousands): June 30, December 31, 2023 2022 Accrued compensation and related expenses $ 1,416 $ 1,909 Accrued clinical 826 1,826 Accrued professional services 33 65 Accrued other 38 112 Total accrued expenses and other liabilities $ 2,313 $ 3,912

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8. Commitments and Contingencies Operating Leases The Company leases office space under various operating leases. Total rent expense for all operating leases in the accompanying condensed consolidated statements of operations and comprehensive loss was $ 0.1 million for each of the three months ended June 30, 2023 and 2022 and $ 0.2 million for each of the six months ended June 30, 2023 and 2022. The Company has an operating lease for 5,197 square feet of office space in Irvine, California. Effective January 1, 2023, the office lease was amended to extend the term of the lease through December 31, 2024 . On November 4, 2021, the Company entered into an operating lease for 6,138 square feet of office space in Burlington, Massachusetts, that expires on November 20, 2024 . The Company determines if a contract contains a lease at inception. Our office leases have a remaining term of approximately twenty-one months and do not include options to extend the leases for additional periods. Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities as adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we estimate incremental secured borrowing rates corresponding to the maturities of the leases. As we have no outstanding debt nor committed credit facilities, secured or otherwise, we estimate this rate based on prevailing financial market conditions, comparable company and credit analysis, and management’s judgment. Our leases contain rent escalations over the lease term. We recognize expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce our right-of-use asset related to the lease. These are amortized through the right-of-use asset as reductions of expense over the lease term. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. While we do not currently have any lease agreement with lease and non-lease components, we elected to account for lease and non-lease components as separate components. We have elected the short-term lease recognition exemption for all applicable classes of underlying assets. Short-term disclosures include only those leases with a term greater than one month and 12 months or less, and expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less, that do not include an option to purchase the underlying asset that we are reasonably certain to exercise, are not recorded on the condensed consolidated balance sheet. The components of lease expense were as follows (in thousands): For the Six Months 2023 2022 Operating lease cost (a) $ 199 $ 203 (a) Includes variable operating lease expenses, which are immaterial Other information related to leases was as follows (in thousands, except lease term and discount rate): For the Six Months 2023 2022 Supplemental Cash Flows Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 181 $ 193 Remaining lease term Operating leases 1.45 years 1.91 years Discount rate Operating leases 2.49 % 3.00 % Future payments under noncancelable operating leases having initial or remaining terms of one year or more are as follows for the succeeding fiscal year and thereafter (in thousands): June 30, 2023 2023 (remainder of) $ 197 2024 388 Total minimum lease payments 585 Less imputed interest ( 11 ) Present value of lease liabilities 574 Less current portion of operating lease liabilities ( 390 ) Non-current operating lease liabilities $ 184 Grants and Licenses ALS Therapy Development Foundation, Inc. License Agreement In May 2015, Anelixis executed a License Agreement (the “Agreement”), which is an exclusive patent rights agreement with ALS Therapy Development Foundation, Inc. (“ALS TDI”) for certain patents and “know-how” of ALS TDI. This Agreement continues until the licensee terminates the agreement with ninety days written notice. The Agreement requires license fees payable to ALS TDI, subject to the achievement of certain milestones and other conditions. The first and second milestones of the Agreement are the dosing of the first subjects in a first toxicity study in non-human primates and the dosing of the first patient in a Phase I Clinical Trial, respectively. Both of these milestones were achieved as of December 31, 2018 and 2017. The fee due for the achievement of these milestones was $ 1.0 million each. During 2018 and 2017, Anelixis issued $ 1.0 million worth of its common stock in lieu of making a cash payment. No milestones were achieved during either the six months ended June 30, 2023 or the year ended December 31, 2022. The Agreement was amended and restated in February 2020, and a first amendment to the restated license agreement was executed in September 2020. As amended in September 2020, the remaining milestone payments for a first licensed product total $ 6.0 million. In the event that the Company develops a second licensed product, the Company is obligated to pay up to $ 2.5 million in additional milestone payments. In addition to the milestone payments, the Company is required to pay ALS TDI an amended annual license maintenance fee of $ 0.1 million beginning on the earlier of January 1, 2022, the Company’s first sublicense, or change in control, as defined in the Agreement. Beginning in 2022, the Company began paying the $0.1 million annual license maintenance fee to ALS TDI. Furthermore, the Company shall pay ALS TDI fees based on reaching certain levels of annual net sales of any product produced with the patent rights. A royalty in the low single digits will be due on aggregate net sales. Upon the first calendar year of reaching $ 500.0 million in aggregate net sales, the Company shall pay ALS TDI a one-time milestone payment of $ 15.0 million. Upon the first calendar year of reaching $ 1.0 billion in aggregate net sales, the Company is obligated to pay ALS TDI a one-time milestone payment of $ 30.0 million. Lonza Sales AG Inc. License Agreement In September 2018, Anelixis executed a License Agreement (the “Lonza Agreement”), which is a manufacturing know-how rights agreement with Lonza Sales AG Inc. (“Lonza”) for the use of certain processes and know-how related to the manufacture of tegoprubart. The Lonza Agreement continues until the later of the last Valid Claim (as defined therein) or ten years from the First Commercial Sale of tegoprubart, as defined and subject to the conditions therein. A royalty in the low single digits will be due on aggregate net sales of tegoprubart that is manufactured by Lonza or any other third-party or licensee. eGenesis, Inc. Collaboration Agreement In September 2022, and subsequently amended in January 2023, Eledon executed a collaborative research agreement with eGenesis, Inc. (the “eGenesis Agreement”), under which eGenesis will gain access to tegoprubart for eGenesis’ ongoing preclinical research and development xenotransplant studies of human-compatible organs and cells for the treatment of organ failure. eGenesis will pay Eledon for supplies of tegoprubart based on the number of study days per animal needed for the eGenesis preclinical xenotransplant studies. The eGenesis agreement continues until September 2025, unless terminated earlier by either party. Israeli Innovation Authority Grant From 2012 through 2015, the Company received grants in the amount of approximately $ 0.5 million from the Israeli Innovation Authority (previously the Office of Chief Scientist) of the Israeli Ministry of Economy and Industry designated for investments in research and development. The grants are linked to the U.S. Dollar and bear annual interest of LIBOR. The grants are to be repaid out of royalties from sales of the products developed by the Company from its investments in research and development. Because the Company has not yet earned revenues related to these investments and cannot estimate potential royalties, no liabilities related to these grants have been recorded as of each period presented. Repayment of the grant is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants if the research and development program fails, is unsuccessful or aborted or if no sales are generated. The Company has not yet generated sales as of June 30, 2023; therefore, no liability was recorded for the repayment in the accompanying condensed consolidated financial statements. Legal Matters The Company and its subsidiaries are not a party to or the subject of any claim or lawsuit that individually or in the aggregate is anticipated to have a material effect on the Company’s results of operations, financial condition or cash flows. Indemnifications In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves future claims that may be made against the Company but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future because of these indemnification obligations. No amounts associated with such indemnifications have been recorded to date. Contingencies From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There have been no contingent liabilities requiring accrual at June 30, 2023.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders' Equity	Note 9. Stockholders’ Equity 2021 Equity Distribution Agreement On March 31, 2021, the Company filed a registration statement on Form S-3 containing a prospectus and prospectus supplement under which the Company may offer and sell up to $ 75 million in shares of its common stock, from time to time, pursuant to an open market sale agreement with Jeffries LLC and by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933 (the “ATM Program”). Pursuant to the “baby shelf rules” promulgated by the SEC, if the Company’s public float is less than $ 75.0 million as of specified measurement periods, the number of shares of common stock that may be offered and sold by the Company under a Form S-3 registration statement, including pursuant to the ATM Program, in any twelve-month period is limited to an aggregate amount that does not exceed one-third of the Company’s public float. As of June 30, 2023 , the Company was permitted to sell up to $ 17.8 million of shares of common stock pursuant to the ATM Program under the SEC’s “baby shelf” rules. The Company will remain subject to the “baby shelf rules” under the Form S-3 registration statement until such time as its public float exceeds $ 75.0 million. Through June 30, 2023 , no shares of common stock have been sold under the ATM program. Under the Securities Purchase Agreement described below in this Note 9, the Company is restricted from selling shares under the ATM Program until the later of (i) 4 months from April 28, 2023 and (ii) ninety days after the registration statement filed pursuant to the Securities Purchase Agreement has been declared effective. The registration statement filed pursuant to the Securities Purchase Agreement was declared effective on June 2, 2023. 2022 Exchange Agreement On January 11, 2022, the Company entered into an exchange agreement (the “Series X 1 Exchange Agreement”) with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, L.L.C. (collectively, the “BVF Exchanging Stockholders”), pursuant to which the Series X 1 Exchanging Stockholders exchanged (the “Series X 1 Exchange”) 550,000 shares of the Company’s common stock for 9,899.99 shares of Series X 1 Non-Voting Convertible Preferred Stock. 2023 Securities Purchase Agreement On April 28, 2023, the Company entered into the Securities Purchase Agreement with Purchasers, pursuant to which the Company agreed to issue and sell to the Purchasers in the Private Placement (i) in an initial closing, (a) an aggregate of 15,151,518 shares (the “Shares”) of the Company’s common stock, $ 0.001 par value per share, or pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”), and (b) common stock warrants exercisable into an aggregate of 15,151,518 shares of common stock (or Pre-Funded Warrants in lieu thereof) (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”); (ii) in a second closing, upon the satisfaction of specified conditions set forth in the Securities Purchase Agreement, an aggregate of 20,202,024 shares of common stock (or Pre-Funded Warrants); and (iii) in a third closing, upon the satisfaction of specified conditions set forth in the Securities Purchase Agreement, an aggregate of 25,252,530 shares of common stock (or Pre-Funded Warrants), in each case subject to customary adjustments as provided in the Securities Purchase Agreement, Pre-Funded Warrant or Common Warrant, as applicable. Each Common Warrant has an exercise price of $ 3.00 per share and expires five years after issuance. The Pre-Funded Warrants are exercisable immediately and until exercised in full, with an exercise price of $ 0.001 per share . The Shares, the Warrants, and the shares of common stock issuable upon the exercise of the Warrants, have not been registered under the Securities Act of 1933, as amended, and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder. On May 5, 2023, the initial closing occurred and the Company received $ 35.0 million, or net proceeds of approximately $ 33.0 million after deducting offering costs, in exchange for 8,730,168 shares of common stock and Pre-Funded Warrants to purchase 6,421,350 shares of common stock. The Company may receive an additional $ 105.0 million upon sale of the shares to be issued in the second and third closings, subject to achieving specified clinical development milestones and volume weighted average share price levels and trading volume conditions, and an additional $ 45.5 million assuming the exercise of all Common Warrants issued in the initial closing of the Private Placement. In connection with the Private Placement, the Company filed on May 18, 2023, a registration statement on Form S-3 (“Registration Statement”) with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The Registration Statement became effective on June 2, 2023. 2023 Conversion Agreement of Non-Voting Convertible Preferred Stock On May 16, 2023, Cormorant Global Healthcare Master Fund LP provided notice to convert (i) 1,782 shares of Series X Non-Voting Convertible Preferred Stock for 99,000 shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X Non-Voting Convertible Preferred Stock, and (ii) 7,883.586 shares of Series X 1 Non-Voting Convertible Preferred Stock for 437,977 shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X 1 Non-Voting Convertible Preferred Stock. The conversion was completed on May 23, 2023. Common Stock Warrants As of June 30, 2023 , there were 22,718,499 warrants exercisable into common stock (rounding for fractional shares and subject to beneficial ownership blockers). Roll Forward of Warrant Activity Private placement warrants Pre-funded warrants Warrants exchanged for Series X 1 preferred stock Total Balance as of December 31, 2022 337,822 509,117 298,692 1,145,631 Issued 15,151,518 6,421,350 — 21,572,868 Exercised — — — — Cancelled/Expired — — — — Balance as of June 30, 2023 15,489,340 6,930,467 298,692 22,718,499 Preferred Stock Warrants As of June 30, 2023 , there were 50,207.419 warrants exercisable into Series X 1 Preferred Stock, which are convertible into 2,789,301 shares of common stock (rounding for fractional shares and subject to beneficial ownership conversion blockers). Roll Forward of Series X 1 Convertible Preferred Warrant Activity Total Balance as of December 31, 2022 50,207.419 Assumed and replaced — Exercised — Cancelled/Expired — Balance as of June 30, 2023 50,207.419

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-based Compensation The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value. The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions which are subjective and require significant judgment and estimation by management. The risk-free rate assumption was based on observed yields from governmental zero-coupon bonds with an equivalent term. The expected volatility assumption was based on historical volatilities of a group of comparable industry companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical industry. The expected term of stock options represents the weighted-average period that the stock options are expected to be outstanding. Because the Company does not have historical exercise behavior, the Company determined the expected life assumption using the simplified method for stock options granted to employees, which is an average of the options ordinary vesting period and the contractual term. For stock options granted to the Company’s board of directors (the “Board”), the Company determined the expected life assumption using the simplified method as the starting point with an average period of twelve (12) months added to take into account for the extended range of time of 12 to 18 months vested stock options granted to Board members may be exercised upon termination. The expected dividend assumption was based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not expect to pay dividends at any time in the foreseeable future. The Company recognizes forfeitures on an actual basis and as such did not estimate forfeitures to calculate stock-based compensation. Restricted Stock Units (“RSUs”) are measured and recognized based on the quoted market price of our common stock on the date of grant. In March 2020, the Board approved an increase of 28,816 shares issuable under the 2014 Stock Incentive Plan (the “2014 Plan”) and 7,204 shares issuable under the 2014 Employee Stock Purchase Plan (the “ESPP”). On December 18, 2020, the Company held a special meeting of its stockholders (the “Special Meeting”), whereby the Company’s stockholders approved the 2020 Long Term Incentive Plan (the “2020 Plan”). The aggregate number of shares of stock initially available for issuance under the 2020 Plan was 4,860,000 shares of common stock, which represented approximately 15 % of the total issued and outstanding shares of the Company’s common stock as of the record date of the Special Meeting (calculated on an as-converted basis and without regard to the potential application of beneficial ownership conversion limitations on the Preferred Stock) and may be increased by the number of shares under the 2014 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company. On June 21, 2023, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the 2020 Plan. The 2020 Plan, as amended, (i) reflects an increase in the limit on the aggregate number of shares of the Company’s common stock that may be delivered pursuant to all awards granted under the 2020 Incentive Plan by an additional 9,600,000 shares so that the new aggregate share limit under the 2020 Plan is 14,460,000 shares, and (ii) extends the date through which the Company may grant new awards under the 2020 Plan from November 15, 2030 to April 26, 2033. On May 1, 2023, the Company issued stock option awards to its employees with both time-based and performance-based vesting requirements, with 1,292,172 of the granted stock options subject to the Company’s customary time-based vesting schedule. The remaining 5,168,685 stock options granted are subject to both customary time-based vesting requirements and performance-based vesting requirements that are based on the same clinical development milestones applicable to the second and third closings of the Private Placement as specified in the Securities Purchase Agreement. No specified clinical development milestones were achieved during the six months ended June 30, 2023. The 2014 Plan was closed to new grants following the initial approval of the 2020 Plan, and therefore, there were no shares reserved for issuance under the 2014 Plan as of June 30, 2023 . The number of shares reserved for issuance under the 2020 Plan and ESPP was 2,995,096 and 24,077 shares, respectively, as of June 30, 2023. Total stock-based compensation expense was recognized in our condensed consolidated statements of operations and comprehensive loss as follows (in thousands): For the Three Months For the Six Months 2023 2022 2023 2022 Research and development $ 455 $ 924 $ 852 $ 1,804 General and administrative 1,265 1,384 2,249 2,690 Total stock-based compensation $ 1,720 $ 2,308 $ 3,101 $ 4,494

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	Note 11. Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, incentive stock options, restricted stock units and warrants are considered to be potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share was the same for the periods presented due to the Company’s net loss position. Basic weighted average shares outstanding for the three and six months ended June 30, 2023 include 6,930,467 shares underlying pre-funded warrants to purchase common shares. As the shares underlying these pre-funded warrants can be issued for little consideration (an exercise price per share equal to $ 0.001 per share), these shares are deemed to be issued for purposes of basic earnings per share. For the Three Months For the Six Months 2023 2022 2023 2022 (In thousands, except share and per share data) Net loss used in the calculation of basic and diluted loss per share $ ( 9,579 ) $ ( 9,247 ) $ ( 20,351 ) $ ( 19,111 ) Net loss per share, basic and diluted $ ( 0.40 ) $ ( 0.65 ) $ ( 1.06 ) $ ( 1.34 ) Weighted-average number of common shares, basic and diluted 24,006,549 14,265,905 19,173,080 14,299,969 The computation of diluted earnings per share exclude s incentive stock options, restricted stock units and warrants that are anti-dilutive. The following table provides a summary as of June 30, 2023 and 2022 of common share equivalents that were excluded because their inclusion would have been anti-dilutive. For the Six Months 2023 2022 Stock options outstanding 6,686,360 5,194,353 Common and preferred warrants outstanding 18,577,332 3,127,121 Total 25,263,692 8,321,474

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 12. Subsequent Events On July 10, 2023, Armistice Capital Master Fund Ltd. (the “Exercising Stockholder”), exercised Pre-Funded Warrants to purchase 501,197 shares of common stock at an exercise price of $ 0.001 per share, which were issued in conjunction with the Securities Purchase Agreement. On July 14, 2023, the Company issued 501,197 shares of common stock to the Exercising Stockholder in accordance with such exercise.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and Article 8 of Regulation S-X requirements as set forth by the Securities and Exchange Commission (“SEC”) for interim financial information and reflect all adjustments and disclosures, which are, in the opinion of management, of a normal and recurring nature, and considered necessary for a fair presentation of the financial information contained herein. Pursuant to these rules and regulations, the unaudited condensed consolidated financial statements do not include all information and notes necessary for a complete presentation of results of operations and comprehensive loss, financial position, and cash flows in conformity with GAAP. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and accompanying notes of Eledon for the year ended December 31, 2022 included in the Annual Report on Form 10-K filed by the Company with the SEC on March 30, 2023. The results of operations and comprehensive loss for the three and six months ended June 30, 2023 are not necessarily indicative of results expected for the full fiscal year or any other future period.
Principles of Consolidation	Principles of Consolidation Eledon, a Delaware corporation, owns 100 % of the issued and outstanding common stock or other ownership interest in Anelixis Therapeutics, LLC, a Delaware limited liability company, and Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel (“Otic”). Otic owns 100 % of the issued and outstanding common stock or other ownership interest in its U.S. subsidiary, Otic Pharma, Inc. The functional currency of the Company’s foreign subsidiary is the U.S. Dollar; however, certain expenses, assets and liabilities are transacted at the local currency. These transactions are translated from the local currency into U.S. Dollars at exchange rates during or at the end of the reporting period. The activities of the Company’s foreign subsidiary are not significant to the condensed consolidated financial statements. All significant intercompany accounts and transactions among the entities have been eliminated from the condensed consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, U.S. government securities and U.S. government agency securities. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments.
Risks and Uncertainties	Risks and Uncertainties As of June 30, 2023 and December 31, 2022, all of the Company’s long-lived assets were located in the United States. The Company’s products will require approval from the U.S. Food and Drug Administration (“FDA”) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company’s business in the future. In addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process. The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional financing. Our facilities and equipment, including those of our suppliers and vendors, may be affected by natural or man-made disasters. Our administrative office is based in Irvine, California and we manage all our research and development activities through third parties that are located throughout the world. We have taken precautions to safeguard our facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, our facilities and systems, as well as those of our third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in our operations, damage or destroy our equipment or inventory, and cause us to incur additional expenses and delay research and development activities. In addition, the insurance coverage we maintain may not be adequate to cover our losses in any circumstance and may not continue to be available to use on acceptable terms, or at all.
Research and Development Expenses	Research and Development Expenses Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed. The Company contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company’s accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company’s prior‑period accrued estimates for clinical trial activities during the three and six months ended June 30, 2023 .
Recently Issued or Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements No new accounting pronouncement issued or effective during the fiscal period had or is expected to have a material impact on the Company’s condensed consolidated financial statements or disclosures.

Short-Term Investments (Tables)

Short-Term Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Summary of Short-term Investments Classified as Available-for-sale Securities	The following is a summary of short-term investments, which were classified as available-for-sale securities as of June 30, 2023: June 30, 2023 Amortized Cost Fair Value U.S. government securities $ 17,642 $ 17,642 U.S. government agency securities 12,789 $ 12,789 Total short-term investments $ 30,431 $ 30,431

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Table Text Block Supplement [Abstract]
Financial Instruments Measured At Fair Value On A Recurring Basis	The following summarizes the Company's financial instruments measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions. June 30, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 5,143 $ — $ — $ 5,143 U.S. government securities — 32,843 — 32,843 U.S. government agency securities — 993 — 993 Total cash equivalents $ 5,143 $ 33,836 $ — $ 38,979 Short-term investments: U.S. government securities $ — $ 17,642 $ — $ 17,642 U.S. government agency securities — 12,789 — 12,789 Total short-term investments $ — $ 30,431 $ — $ 30,431 Total financial assets $ 5,143 $ 64,267 $ — $ 69,410 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 9,296 $ — $ — $ 9,296 U.S. government securities — — — — U.S. government agency securities — — — — Total cash equivalents $ 9,296 $ — $ — $ 9,296 Short-term investments: U.S. government securities $ — $ — $ — $ — U.S. government agency securities — — — — Total short-term investments $ — $ — $ — $ — Total financial assets $ 9,296 $ — $ — $ 9,296

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): June 30, December 31, 2023 2022 Prepaid insurance $ 315 $ 823 Prepaid clinical 1,445 2,115 Prepaid other 246 143 Other current assets 238 28 Total prepaid expenses and other current assets $ 2,244 $ 3,109

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consisted of the following (in thousands): June 30, December 31, 2023 2022 Accrued compensation and related expenses $ 1,416 $ 1,909 Accrued clinical 826 1,826 Accrued professional services 33 65 Accrued other 38 112 Total accrued expenses and other liabilities $ 2,313 $ 3,912

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Components of Lease Expense	The components of lease expense were as follows (in thousands): For the Six Months 2023 2022 Operating lease cost (a) $ 199 $ 203 (a) Includes variable operating lease expenses, which are immaterial
Schedule of Other Information Related to Leases	Other information related to leases was as follows (in thousands, except lease term and discount rate): For the Six Months 2023 2022 Supplemental Cash Flows Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 181 $ 193 Remaining lease term Operating leases 1.45 years 1.91 years Discount rate Operating leases 2.49 % 3.00 %
Schedule of Future Payments Under Noncancelable Operating Leases	Future payments under noncancelable operating leases having initial or remaining terms of one year or more are as follows for the succeeding fiscal year and thereafter (in thousands): June 30, 2023 2023 (remainder of) $ 197 2024 388 Total minimum lease payments 585 Less imputed interest ( 11 ) Present value of lease liabilities 574 Less current portion of operating lease liabilities ( 390 ) Non-current operating lease liabilities $ 184

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Common Stock Warrants [Member]
Class Of Stock [Line Items]
Schedule of Warrant Activity	As of June 30, 2023 , there were 22,718,499 warrants exercisable into common stock (rounding for fractional shares and subject to beneficial ownership blockers). Roll Forward of Warrant Activity Private placement warrants Pre-funded warrants Warrants exchanged for Series X 1 preferred stock Total Balance as of December 31, 2022 337,822 509,117 298,692 1,145,631 Issued 15,151,518 6,421,350 — 21,572,868 Exercised — — — — Cancelled/Expired — — — — Balance as of June 30, 2023 15,489,340 6,930,467 298,692 22,718,499
Preferred Stock Warrants [Member]
Class Of Stock [Line Items]
Schedule of Warrant Activity	As of June 30, 2023 , there were 50,207.419 warrants exercisable into Series X 1 Preferred Stock, which are convertible into 2,789,301 shares of common stock (rounding for fractional shares and subject to beneficial ownership conversion blockers). Roll Forward of Series X 1 Convertible Preferred Warrant Activity Total Balance as of December 31, 2022 50,207.419 Assumed and replaced — Exercised — Cancelled/Expired — Balance as of June 30, 2023 50,207.419

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense Recognized	Total stock-based compensation expense was recognized in our condensed consolidated statements of operations and comprehensive loss as follows (in thousands): For the Three Months For the Six Months 2023 2022 2023 2022 Research and development $ 455 $ 924 $ 852 $ 1,804 General and administrative 1,265 1,384 2,249 2,690 Total stock-based compensation $ 1,720 $ 2,308 $ 3,101 $ 4,494

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share	basic and diluted net loss per share was the same for the periods presented due to the Company’s net loss position. For the Three Months For the Six Months 2023 2022 2023 2022 (In thousands, except share and per share data) Net loss used in the calculation of basic and diluted loss per share $ ( 9,579 ) $ ( 9,247 ) $ ( 20,351 ) $ ( 19,111 ) Net loss per share, basic and diluted $ ( 0.40 ) $ ( 0.65 ) $ ( 1.06 ) $ ( 1.34 ) Weighted-average number of common shares, basic and diluted 24,006,549 14,265,905 19,173,080 14,299,969
Summary of Common Share Equivalents Excluded Due to Anti-dilutive	The computation of diluted earnings per share exclude s incentive stock options, restricted stock units and warrants that are anti-dilutive. The following table provides a summary as of June 30, 2023 and 2022 of common share equivalents that were excluded because their inclusion would have been anti-dilutive. For the Six Months 2023 2022 Stock options outstanding 6,686,360 5,194,353 Common and preferred warrants outstanding 18,577,332 3,127,121 Total 25,263,692 8,321,474

Description of Business - Addit

Description of Business - Additional Information (Detail)	Sep. 14, 2020
Anelixis [Member]
Description Of Business [Line Items]
Date of acquisition	Sep. 14, 2020

Going Concern and Management'_2

Going Concern and Management's Plans (Additional Information) (Detail) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended
	May 05, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Apr. 28, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss used in the calculation of basic and diluted loss per share		$ (9,579)	$ (10,772)	$ (9,247)	$ (9,864)	$ (20,351)	$ (19,111)
Accumulated deficit		(223,216)				(223,216)			$ (202,865)
Cash and cash equivalents		40,947				40,947			$ 56,409
Cash and cash equivalents and short-term investments		$ 71,400				$ 71,400
Common stock, shares issued		23,043,933				23,043,933			13,776,788
Securities Purchase Agreement Initial Closing [Member] | Private Placement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common warrants issued	$ 35,000
Securities Purchase Agreement Initial Closing [Member] | Private Placement [Member] | Pre-funded Warrants [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares issued	6,421,350
Securities Purchase Agreement Initial Closing [Member] | Accredited Investor [Member] | Private Placement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common warrants issued	$ 45,500
Common stock, shares issued	8,730,168							15,151,518
Common stock warrants to purchase common stock shares	15,151,518							15,151,518
Securities Purchase Agreement Second and Third Closing [Member] | Accredited Investor [Member] | Private Placement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common warrants issued	$ 105,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2023
Anelixis Therapeutics, LLC and Otic Pharma, Ltd.
Summary Of Significant Accounting Policies [Line Items]
Ownership interest percentage	100%
Otic Pharma, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Ownership interest percentage	100%

Short-Term Investments - Summar

Short-Term Investments - Summary of Short-term Investments Classified as Available-for-sale Securities (Detail) $ in Thousands	Jun. 30, 2023 USD ($)
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	$ 30,431
Fair Value	30,431
U.S. Government Securities [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	17,642
Fair Value	17,642
U.S. Government Agency Securities [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	12,789
Fair Value	$ 12,789

Short-Term Investments - Additi

Short-Term Investments - Additional Information (Detail) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Short-term investments	$ 30,431,000	$ 0

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail) - Fair Value, Recurring Member - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	$ 38,979	$ 9,296
Total short-term investments	30,431
Total financial assets	69,410	9,296
Money Market Funds Member
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	5,143	9,296
U.S. Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	32,843
Total short-term investments	17,642
U.S. Government Agency Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	993
Total short-term investments	12,789
Fair Value Inputs Level1 Member
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	5,143	9,296
Total financial assets	5,143	9,296
Fair Value Inputs Level1 Member | Money Market Funds Member
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	5,143	$ 9,296
Fair Value Inputs Level2 Member
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	33,836
Total short-term investments	30,431
Total financial assets	64,267
Fair Value Inputs Level2 Member | U.S. Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	32,843
Total short-term investments	17,642
Fair Value Inputs Level2 Member | U.S. Government Agency Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total cash equivalents	993
Total short-term investments	$ 12,789

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid insurance	$ 315	$ 823
Prepaid clinical	1,445	2,115
Prepaid other	246	143
Other current assets	238	28
Total prepaid expenses and other current assets	$ 2,244	$ 3,109

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accrued Liabilities and Other Liabilities [Abstract]
Accrued compensation and related expenses	$ 1,416	$ 1,909
Accrued clinical	826	1,826
Accrued professional services	33	65
Accrued other	38	112
Total accrued expenses and other liabilities	$ 2,313	$ 3,912

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)			3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 01, 2023	Nov. 04, 2021 ft²	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) ft² Milestone	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) Milestone	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2015 USD ($)
Other Commitments [Line Items]
Rental expense			$ 100,000	$ 100,000	$ 200,000	$ 200,000
Indemnification obligations amount			0		0
Contingent Liabilities			0		$ 0
Office of Chief Scientist of Israeli Ministry of Economy and Industry [Member]
Other Commitments [Line Items]
Grants received											$ 500,000
ALS Therapy Development Foundation, Inc. License Agreement [Member]
Other Commitments [Line Items]
Fee due for milestones achieved								$ 1,000,000	$ 1,000,000
Common stock issued in lieu of making a cash payment								$ 1,000,000	$ 1,000,000
Number of Milestones Achieved | Milestone					0		0
Remaining milestone payments for first licensed product										$ 6,000,000
Annual License Maintenance Fee							$ 100,000
ALS Therapy Development Foundation, Inc. License Agreement [Member] | Achievement of 500 Million Aggregate Sales [Member]
Other Commitments [Line Items]
Reaching of aggregate net sales					$ 500,000,000
Amount of one-time milestone payment			15,000,000		15,000,000
ALS Therapy Development Foundation, Inc. License Agreement [Member] | Achievement of 1 Billion Aggregate Sales [Member]
Other Commitments [Line Items]
Reaching of aggregate net sales					1,000,000,000
Amount of one-time milestone payment			$ 30,000,000		$ 30,000,000
Maximum [Member] | ALS Therapy Development Foundation, Inc. License Agreement [Member]
Other Commitments [Line Items]
Development and regulatory milestone payments										$ 2,500,000
Irvine, California [Member]
Other Commitments [Line Items]
Area of office space | ft²					5,197
Lease expiration date	Dec. 31, 2024
Burlington, Massachusetts [Member]
Other Commitments [Line Items]
Area of office space | ft²		6,138
Lease expiration date		Nov. 20, 2024

Commitments and Contingencies_2

Commitments and Contingencies - Components of Lease Expense (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 199	$ 203

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Other Information Related to Leases (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 181	$ 193
Remaining lease term
Operating leases	1 year 5 months 12 days	1 year 10 months 28 days
Discount rate
Operating leases	2.49%	3%

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
2023 (remainder of)	$ 197
2024	388
Total minimum lease payments	585
Less imputed interest	(11)
Present value of lease liabilities	574
Less current portion of operating lease liabilities	(390)	$ (363)
Non-current operating lease liabilities	$ 184	$ 383

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)				6 Months Ended
	May 16, 2023	May 05, 2023	Jan. 11, 2022	Jun. 30, 2023	Apr. 28, 2023	Dec. 31, 2022	Mar. 31, 2021
Class Of Stock [Line Items]
Warrants available for exercise				22,718,499
Debt outstanding				$ 0
Common stock, shares issued				23,043,933		13,776,788
Common stock, par value, per share				$ 0.001		$ 0.001
Net proceeds after deducting offering costs				$ 33,017,000
Securities Purchase Agreement [Member]
Class Of Stock [Line Items]
Number of days after registration settlement				90 days
Series X1 Preferred Stock [Member]
Class Of Stock [Line Items]
Warrants available for exercise				50,207.419
Shares of common stock issued upon conversion of each share of preferred stock				2,789,301
Common Stock [Member]
Class Of Stock [Line Items]
Warrants available for exercise				22,718,499
Private Placement Warrants [Member]
Class Of Stock [Line Items]
Warrants available for exercise				15,489,340
Private Placement Warrants [Member] | Accredited Investor [Member]
Class Of Stock [Line Items]
Warrants exercise price					$ 3
Private Placement Warrants [Member] | Securities Purchase Agreement Initial Closing [Member]
Class Of Stock [Line Items]
Common warrants issued		$ 35,000,000
Net proceeds after deducting offering costs		$ 33,000,000
Private Placement Warrants [Member] | Securities Purchase Agreement Initial Closing [Member] | Accredited Investor [Member]
Class Of Stock [Line Items]
Common stock, shares issued		8,730,168			15,151,518
Common stock, par value, per share					$ 0.001
Common stock warrants exercisable		15,151,518			15,151,518
Common warrants issued		$ 45,500,000
Private Placement Warrants [Member] | Securities Purchase Agreement Second Closing [Member] | Accredited Investor [Member]
Class Of Stock [Line Items]
Common stock, shares issued					20,202,024
Private Placement Warrants [Member] | Securities Purchase Agreement Third Closing [Member] | Accredited Investor [Member]
Class Of Stock [Line Items]
Common stock, shares issued					25,252,530
Private Placement Warrants [Member] | Securities Purchase Agreement Second and Third Closing [Member] | Accredited Investor [Member]
Class Of Stock [Line Items]
Common warrants issued		$ 105,000,000
Private Placement Warrants [Member] | Common Stock [Member] | Securities Purchase Agreement Initial Closing [Member]
Class Of Stock [Line Items]
Common stock, shares issued		8,730,168
Private Placement Warrants [Member] | Pre-funded Warrants [Member] | Accredited Investor [Member]
Class Of Stock [Line Items]
Warrants exercise price					$ 0.001
Private Placement Warrants [Member] | Pre-funded Warrants [Member] | Securities Purchase Agreement Initial Closing [Member]
Class Of Stock [Line Items]
Common stock, shares issued		6,421,350
Jeffries LLC [Member] | ATM Program [Member]
Class Of Stock [Line Items]
Common stock number of shares issued				0
Equity distribution agreement maximum value of common shares issuable							$ 75,000,000
Public float minimum balance to be maintained				$ 75,000,000
Jeffries LLC [Member] | Maximum [Member] | ATM Program [Member]
Class Of Stock [Line Items]
Equity distribution agreement maximum value of common shares issuable				$ 17,800,000
BVF Exchanging Stockholders [Member] | Series X1 Non-voting Convertible Preferred Stock [Member] | Series X1 Exchange Agreement [Member]
Class Of Stock [Line Items]
Conversion of stock, shares issued			9,899.99
BVF Exchanging Stockholders [Member] | Common Stock [Member] | Series X1 Exchange Agreement [Member]
Class Of Stock [Line Items]
Conversion of stock, shares converted			550,000
Cormorant Global Healthcare Master Fund LP [Member] | Series X Non-Voting Convertible Preferred Stock [Member] | Conversion Agreement [Member]
Class Of Stock [Line Items]
Conversion of stock, shares converted	1,782
Cormorant Global Healthcare Master Fund LP [Member] | Series X1 Non-voting Convertible Preferred Stock [Member] | Conversion Agreement [Member]
Class Of Stock [Line Items]
Conversion of stock, shares converted	7,883.586
Cormorant Global Healthcare Master Fund LP [Member] | Common Stock [Member] | Series X Non-Voting Convertible Preferred Stock [Member] | Conversion Agreement [Member]
Class Of Stock [Line Items]
Conversion of stock, shares issued	99,000
Cormorant Global Healthcare Master Fund LP [Member] | Common Stock [Member] | Series X1 Non-voting Convertible Preferred Stock [Member] | Conversion Agreement [Member]
Class Of Stock [Line Items]
Conversion of stock, shares issued	437,977

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Warrant Activity (Detail)	6 Months Ended
	Jun. 30, 2023 shares
Class Of Warrant Or Right [Line Items]
Ending Balance	22,718,499
Private Placement Warrants [Member]
Class Of Warrant Or Right [Line Items]
Ending Balance	15,489,340
Pre-funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Ending Balance	6,930,467
Warrants Exchanged for Series X1 Preferred Stock [Member]
Class Of Warrant Or Right [Line Items]
Ending Balance	298,692
Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Beginning Balance	1,145,631
Issued	21,572,868
Exercised	0
Cancelled/Expired	0
Common Stock Warrants [Member] | Private Placement Warrants [Member]
Class Of Warrant Or Right [Line Items]
Beginning Balance	337,822
Issued	15,151,518
Exercised	0
Cancelled/Expired	0
Common Stock Warrants [Member] | Pre-funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Beginning Balance	509,117
Issued	6,421,350
Exercised	0
Cancelled/Expired	0
Common Stock Warrants [Member] | Warrants Exchanged for Series X1 Preferred Stock [Member]
Class Of Warrant Or Right [Line Items]
Beginning Balance	298,692
Issued	0
Exercised	0
Cancelled/Expired	0

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Series X1 Convertible Preferred Stock Warrant Activity (Detail)	6 Months Ended
	Jun. 30, 2023 shares
Class Of Warrant Or Right [Line Items]
Ending Balance	22,718,499
Preferred Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Beginning Balance	50,207.419
Assumed and replaced	0
Exercised	0
Cancelled/Expired	0
Ending Balance	50,207.419

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail)				6 Months Ended
	Jun. 21, 2023 shares	May 01, 2023 shares	Dec. 18, 2020 shares	Jun. 30, 2023 Milestone shares	Mar. 31, 2020 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of specific clinical development milestones achieved | Milestone				0
Time-based and Performance-based Vesting Requirements [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options granted		5,168,685
Time-based Vesting Requirements [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options granted		1,292,172
2014 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Increase in number of shares of common stock authorized for issuance					28,816
Common stock, number of shares initially reserved for issuance				0
2014 Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Increase in number of shares of common stock authorized for issuance					7,204
Common stock, number of shares initially reserved for issuance				24,077
2020 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, number of shares initially reserved for issuance			4,860,000	2,995,096
Percentage of issued and outstanding shares of common stock			15%
Increased number of shares	9,600,000
New aggregate share limit	14,460,000
Stock Options [Member] | Board of Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life assumption using simplified method, description				For stock options granted to the Company’s board of directors (the “Board”), the Company determined the expected life assumption using the simplified method as the starting point with an average period of twelve (12) months added to take into account for the extended range of time of 12 to 18 months vested stock options granted to Board members may be exercised upon termination.
Stock Options [Member] | Board of Directors [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period of stock options granted				12 months
Stock Options [Member] | Board of Directors [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period of stock options granted				18 months

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Recognized Stock-Based Compensation (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 1,720	$ 2,308	$ 3,101	$ 4,494
Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	455	924	852	1,804
General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 1,265	$ 1,384	$ 2,249	$ 2,690

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) - Pre-funded Warrants [Member]	Jun. 30, 2023 $ / shares shares
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Common stock warrants exercisable | shares	6,930,467
Warrants exercise price | $ / shares	$ 0.001

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net loss used in the calculation of basic and diluted loss per share	$ (9,579)	$ (10,772)	$ (9,247)	$ (9,864)	$ (20,351)	$ (19,111)
Net loss per share, Basic	$ (0.4)		$ (0.65)		$ (1.06)	$ (1.34)
Net loss per share, Diluted	$ (0.4)		$ (0.65)		$ (1.06)	$ (1.34)
Weighted-average common shares outstanding, Basic	24,006,549		14,265,905		19,173,080	14,299,969
Weighted-average common shares outstanding, Diluted	24,006,549		14,265,905		19,173,080	14,299,969

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Common Share Equivalents Excluded Due to Anti-dilutive (Detail) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share	25,263,692	8,321,474
Stock Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share	6,686,360	5,194,353
Common and Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted earnings per share	18,577,332	3,127,121

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - $ / shares	Jul. 14, 2023	Jul. 10, 2023	Jun. 30, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Common stock, shares issued			23,043,933	13,776,788
Subsequent Event [Member] | Armistice Capital Master Fund Ltd [Member] | Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Number of pre-funded warrants exercised for common stock		501,197
Common stock, shares issued	501,197
Pre-funded warrants, exercise price		$ 0.001